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Gonadotropin-releasing hormone 1 (GnRH1) and its receptor (GnRHR1) drive
mammalian reproduction via regulation of the gonadotropins. Yet, a second form
of GnRH (GnRH2) and its receptor (GnRHR2) also exist in mammals. GnRH2 has
been completely conserved throughout 500 million years of evolution, signifying high
selection pressure and a critical biological role. However, the GnRH2 gene is absent
(e.g., rat) or inactivated (e.g., cow and sheep) in some species but retained in others
(e.g., human, horse, and pig). Likewise, many species (e.g., human, chimpanzee,
cow, and sheep) retain the GnRHR2 gene but lack the appropriate coding sequence
to produce a full-length protein due to gene coding errors; although production of
GnRHR2 in humans remains controversial. Certain mammals lack the GnRHR2 gene
(e.g., mouse) or most exons entirely (e.g., rat). In contrast, old world monkeys, musk
shrews, and pigs maintain the coding sequence required to produce a functional
GnRHR2. Like GnRHR1, GnRHR2 is a 7-transmembrane, G protein-coupled receptor
that interacts with Gαq/11 to mediate cell signaling. However, GnRHR2 retains a cytoplasmic tail and is only 40% homologous to GnRHR1. A role for GnRH2 and its receptor
in mammals has been elusive, likely because common laboratory models lack both the
ligand and receptor. Uniquely, both GnRH2 and GnRHR2 are ubiquitously expressed;
transcript levels are abundant in peripheral tissues and scarcely found in regions of
the brain associated with gonadotropin secretion, suggesting a divergent role from
GnRH1/GnRHR1. Indeed, GnRH2 and its receptor are not physiological modulators
of gonadotropin secretion in mammals. Instead, GnRH2 and GnRHR2 coordinate the
interaction between nutritional status and sexual behavior in the female brain. Within
peripheral tissues, GnRH2 and its receptor are novel regulators of reproductive organs.
GnRH2 and GnRHR2 directly stimulate steroidogenesis within the porcine testis.
In the female, GnRH2 and its receptor may help mediate placental function, implantation, and ovarian steroidogenesis. Furthermore, both the GnRH2 and GnRHR2 genes
are expressed in human reproductive tumors and represent emerging targets for cancer treatment. Thus, GnRH2 and GnRHR2 have diverse functions in mammals which
remain largely unexplored.
Keywords: GnRH2, GnRH2 receptor, reproductive function, G protein-coupled receptor, G protein-coupled
receptor signal transduction, autocrine/paracrine mechanisms, testis, cancer
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BACKGROUND

ancient form of GnRH (18). In contrast, GnRH1 evolved 350
million years ago and its sequence varies greatly among vertebrates (19).

The Classical Form of Mammalian
Gonadotropin-Releasing Hormone
(GnRH1)

The Gene for GnRH2

GnRH2 is not merely a splice variant of the GnRH1 gene; instead,
it is produced from its own gene that encodes the peptide, preproGnRH2 (20). The GnRH2 gene is located on chromosome 20 in
humans, chimpanzees, and orangutans, chromosome 13 in the
cow, chromosome 22 in the horse, chromosome 10 in the rhesus
macaque, and chromosome 17 in the pig (21). The genomic orientation of the GnRH2 gene is highly conserved across species (21, 22).
It is flanked by the PTPRA and MRPS26 genes in all mammalian
and non-mammalian vertebrates examined to date (21, 22). The
PTPRA gene resides about 5–6 kb upstream of the GnRH2 gene
(21) and encodes the enzyme, receptor-type tyrosine-protein
phosphatase α, which is critical for neural development (23). The
MRPS26 gene resides about 300 bp downstream of the GnRH2
gene (21), encoding mitochondrial ribosome protein S26, which
assists in protein synthesis (24). A graphical representation of the
porcine GnRH2 gene is depicted in Figure 1A.
The human GnRH2 gene has three coding exons like the
GnRH1 gene; however, the GnRH2 gene is notably shorter
(2.1 versus 5.1 kb), primarily due to differences in intron length
(20). Otherwise, organization of the GnRH1 and GnRH2 genes
remain similar (25). The first coding exon in humans encodes the
signal sequence, mature decapeptide, and a portion of the GnRHassociated peptide (GAP). The second and third exons encode
the remaining GAP (20). Likewise, porcine prepro-GnRH2
is encoded by 3 exons and yields a 110 amino acid product
(Figure 1B) that must undergo post-translational proteolytic
processing for functionality (20).

The classical, hypophysiotropic GnRH1 is hailed as the master
regulator of reproduction in mammals. GnRH1 is a decapeptide
(pGlu–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly–NH 2 )
produced by hypothalamic neurons and secreted in a pulsatile
manner into hypophyseal portal capillaries where it travels to
the anterior pituitary gland. GnRH1 then binds to its receptor
(GnRHR1) on gonadotrope cells, promoting the synthesis and
secretion of the gonadotropins, follicle-stimulating hormone
(FSH) and luteinizing hormone (LH), into peripheral circulation
where they act on their target organs, the gonads. In females, FSH
stimulates follicular development, whereas LH promotes ovulation and maintenance of the corpus luteum. Within the testes,
FSH regulates spermatogenesis and LH elicits secretion of testosterone. Ultimately, the gonads cease to function and reproduction
is halted in the absence of GnRH1 (1–3).

GnRH Variants in Mammals

Gonadotropin-releasing hormone 1 was first identified in the
hypothalami of pigs and sheep (4–6) and was originally thought
to be a novel peptide. However, 23 other forms of GnRH have
since been discovered (7), all with 10 amino acids and at least
a 50% sequence identity (8). Within these forms, the sequences
of both the N-terminus (pGlu–His–Trp–Ser) and C-terminus
(Pro–Gly–NH2) are conserved (7, 9). The amino acid substitutions only occur between residues 5 and 8 (7, 9). In vertebrates,
three forms of GnRH (GnRH1, GnRH2, and GnRH3) are the
most common. The third form of GnRH (GnRH3; pGlu–His–
Trp–Ser–His–Asp–Trp–Lys–Pro–Gly–NH2) was first discovered
in lamprey (10) but the GnRH3 gene has only been confirmed in
fish and amphibians to date (7, 11). Therefore, only GnRH1 and
GnRH2 are produced in mammals (7).

Presence of the GnRH2 Gene in Mammals

Although the GnRH2 gene was first identified in humans
(20), Stewart et al. (21) examined the genomes of mammals
encompassing 10 orders for the presence of the GnRH2 gene.
The GnRH2 gene was positively identified in 21 animals. Using
bioinformatics, the authors concluded that gene coding errors
likely prevent the successful production of GnRH2 in many
species (21). A summary of the coding errors present in the
GnRH2 gene of mammals is available in Table 1. A premature
stop codon truncates the mature decapeptide in the chimpanzee,
orangutan, mouse lemur, sheep, and cat (21, 26), whereas the
rabbit, pika, cow, dog, cat, and dolphin GnRH2 genes encode
an inactive peptide (21, 26). Early evidence implied that the rat
and mouse also maintain a GnRH2 gene as immunoreactive
GnRH2 was detected in the rodent brain (27–29). Although it
was later determined that the mouse genome only maintains a
fragment of the GnRH2 gene (exon 1) on chromosome 2 and it
is completely deleted from chromosome 3 in the rat (21, 22, 30).
Together, these data reveal that the GnRH2 gene is absent or
functionally inactivated in many mammals. In contrast, 10
species (human, macaque, marmoset, tarsier, tree shrew, guinea
pig, musk shrew, common shrew, horse, and pig) maintain the
appropriate genomic sequence to produce a biologically active

GONADOTROPIN-RELEASING
HORMONE 2
The Second Form of Mammalian GnRH
(GnRH2)

A second structural variant of GnRH, GnRH2, has been identified in mammals. Like GnRH1, GnRH2 is a decapeptide but it
was first isolated from the hypothalami of 10,000 chickens and
therefore named “chicken GnRH2” (12). It was later discovered
in mammals, the first being marsupials (13), and renamed simply
“GnRH2” to prevent confusion (14). Since then, GnRH2 has
been found in animals of every vertebrate class including primitive orders (e.g., bony fish) as well as complex mammals (15).
GnRH2 is absent only in jawless fish (16). Notably, the sequence
of GnRH2 remains entirely conserved throughout evolution,
indicating high selection pressure and a critical function (17).
Absolute conservation of GnRH2 has persisted despite 500 million years of evolution (15), indicating that it may be the most
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Figure 1 | Genomic organization of the porcine GnRH2 gene and its products. (A) The PTPRA gene (green) is located 6.1 kb upstream, whereas the MRPS26
gene (red) is positioned 278 bp downstream of the porcine GnRH2 gene (blue) on chromosome 17. Arrows indicate start codons for each gene. (B) The porcine
GnRH2 gene contains three coding exons and two introns. Exon 1 (~150 bp) of the porcine GnRH2 gene encodes the signaling sequence (SS), mature GnRH2
decapeptide, and a portion of the GnRH-associated peptide (GAP). Exon 2 (~140 bp) and exon 3 (~40 bp) encode the remaining GAP sequence. Note that introns
and exons are not drawn to scale. (C) Amino acid sequence alignments of predicted porcine prepro-GnRH2 isoforms (NCBI accession numbers XP_005672842
and XP_013840618) with porcine prepro-GnRH1 (NCBI accession number NP_999439). Prepro-GnRH1 is 91 amino acids in length compared with prepro-GnRH2,
which has 110 residues. An isoform of prepro-GnRH2 (143 amino acids) is also predicted to be produced from the porcine GnRH2 gene due to alternative splicing.
The amino acids that correspond to the SS, the mature decapeptide, and the GAP are indicated. The proteolytic cleavage sites are highlighted in bold.

decapeptide (21). We re-evaluated the presence of the GnRH2
gene in mammals by surveying updated NCBI gene databases
and found that an additional 68 mammals, comprising 9 additional orders, possess the GnRH2 gene to date (Table 2). Thus,
89 mammals from 19 orders maintain the GnRH2 gene, further
suggesting that the GnRH2 gene was present in a common
mammalian ancestor (21). However, whether the GnRH2 gene
encodes a functional peptide in all of these animals remains
unknown.

(14, 29). In primates and humans, GnRH2 is prevalent in the
caudate nucleus, hippocampus, and amygdala (36, 37) and has
also been detected in the midbrain and hindbrain (7). White
et al. (20) quantified expression of the GnRH2 gene in 50 different human tissues, including numerous regions of the brain
(20). Surprisingly, GnRH2 mRNA was identified in all tissues
examined and levels were highest in peripheral tissues; the
converse was true for GnRH1.
In the periphery, transcript levels for GnRH2 were 30-fold
higher in the kidney and 4-fold higher in bone marrow and the
prostate compared with the brain. GnRH2 is also produced in
organs of the thoracic (e.g., heart, lung, and aorta), digestive (e.g.,
salivary gland, stomach, and intestine), endocrine (e.g., adrenal,
pancreas, and thyroid), and immune (e.g., tonsil, leukocyte, and
lymph node) systems (Table 3) (11, 29). Moreover, GnRH2 has
been identified in numerous female (e.g., ovary, uterus, endometrium, and myometrium) and male (e.g., testis, epididymis,
seminal vesicles, and prostate) reproductive organs (Table 3)
(11, 29). The ubiquitous nature of this decapeptide is also

GnRH2 Is Ubiquitously Expressed within
Mammals

Like GnRH1, GnRH2 has been identified in the pre-optic
and medio-basal hypothalamic areas (7), albeit scarcely (33).
Likewise, our group detected low levels of GnRH2 within the
hypothalamus of the pig, implying that GnRH2 is not a prominent regulator of gonadotropin secretion (34, 35). GnRH2 has
also been discovered in the midbrain and limbic structures,
suggesting a role in the modulation of reproductive behavior
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Table 1 | Presence and potential functionality of the GnRH2 and GnRHR2 genes within mammals.a
Order

Mammal (genus species)

GnRH2

GnRHR2

Gene

Coding disruptionb

Functional
protein

Gene

Coding disruptionb

Functional
protein

Artiodactyla

Alpaca (Vicugna pacos)
Cow (Bos taurus)
Pig (Sus scrofa)
Sheep (Ovis aries)

+
+
+
+

?
AAA
−
PSC

?
−
+
−

+
+
+
+

?
PSC
−
PSC

?
−
+
−

Carnivora

Cat (Felis catus)
Dog (Canis familiaris)

+
+

PSC; FM; AAA
PSC; AAA

−
−

+
+

PSC
PSC; FM

−
−

Cetacea

Bottle-nosed dolphin (Tursiops truncatus)

+

AAA

−

+

FM; AAA; PSC

−

Lagomorpha

Pika (Ochotona princeps)
Rabbit (Oryctolagus cuniculus)

+
+

AAA; BI
MS; PSC

−
−

?
+

?
MS; FM; PSC

?
−

Perissodactyla

Horse (Equus caballus)

+

−

+

+

FM; PSC

−

Primates

African green monkey (Cercopithecus aethiops)
Chimpanzee (Pan troglodytes)
Common marmoset (Callithrix jacchus)
Human (Homo sapien)
Mouse lemur (Microcebus murinus)
Orangutan (Pongo pygmaeus)
Rhesus macaque (Macaca mulatta)
Tarsier (Tarsius syrichta)

?
+
+
+
+
+
+
+

?
PSC
−
−
PSC
PSC
−
−

?
−
+
+
−
−
+
+

+
+
+
+
+
+
+
+

−
FM; PSC
−
FM; PSC
?
−
−
?

+
−
+
−
?
+
+
?

Proboscidea

African elephant (Loxodonta africana)

+

?

?

+

−

+

Rodentia

Ground squirrel (Spermophilus tridecemlineatus)
Guinea pig (Cavia porcellus)
Kangaroo rat (Dipodomys ordii)
Mouse (Mus musculus)
Rat (Rattus norvegicus)

+
+
+
+
−

?
−
?
GR
−

?
+
?
−
−

+
+
+
−
+

PSC; AAA
PSC; FM
AAA
−
GR

−
−
?
−
−

Scandentia

Tree shrew (Tupaia belangeri)

+

−

+

+

−

+

Soricomorpha

Common shrew (Sorex araneus)
Musk shrew (Suncus murinus)c

+
+

−
−

+
+

+
?

BD; FM; PSC
?

−
+

a
Data are based on bioinformatics. Absence of the gene or functional protein is denoted by a (−), whereas presence is indicated by a (+). Species in which there was not enough
genomic information available (or the functionality has not yet been assessed) will be noted as a (?). Adapted from Stewart et al. (21).
b
In many species, the gene for GnRH2 and/or GnRHR2 is present but presumed non-functional due to gene coding errors. If the gene is affected, the nature of the disruption is
indicated. Absence of a gene disruption is indicated by a minus symbol (−).
c
The genome of the musk shrew has not been fully annotated. Therefore, the presence of GnRHR2 in the musk shrew is putative based on the work of Temple et al. (31) and
Kauffman et al. (32) establishing a functional GnRHR2.
Abbreviations: PSC, premature stop codon; FM, frameshift mutation; AAA, amino acid alteration; GR, gene remnant; BI, base insertion; BD, base deletion; MS, missing sequence.

evident in the many immortalized cell lines in which GnRH2
has been isolated, including cells derived from breast tissue
(38), lymphocytes (39), ovaries (40, 41), and neural tissue (42).
A summary of the mammalian cell lines that produce GnRH2
is available in Table 4. Ultimately, these data demonstrate that
GnRH2 is ubiquitously expressed, indicating a divergent function from GnRH1.

the presence of a putative androgen response element and
direct interaction with the androgen receptor was confirmed
via chromatin immunoprecipitation assays (54). In females,
GnRH2 expression in the hypothalamus of rhesus macaques
is stimulated by 17β-estradiol treatment (55). Similarly,
treatment of human granulosa-luteal cells with 17β-estradiol
resulted in a dose-dependent increase in GnRH2 mRNA
expression (56) and 17β-estradiol exerted a stimulatory effect
on GnRH2 expression in human neuronal cells (42). The effect
of progesterone has also been examined in humans. Primary
cultures of human granulosa-luteal cells treated with RU486
(progesterone receptor antagonist) increased GnRH2 expression in a time- and dose-dependent fashion (56). However,
neither progesterone nor RU486 affected GnRH2 expression in
human neuronal cells (57).
There is also evidence that protein hormones modulate
GnRH2 production. Treatment with FSH or human chorionic
gonadotropin (hCG) upregulated GnRH2 gene transcription

Transcriptional Regulation of GnRH2 Gene
Expression

The expression of GnRH2 is regulated by several different
reproductive hormones including androgens, 17β-estradiol,
progesterone, the gonadotropins, and GnRH2 itself. Darby et al.
(54) demonstrated in tumors from prostate cancer patients that
androgens enhance GnRH2 expression. This effect was likely
mediated at the transcriptional level because sequence analysis
of the 5′ flanking region for the human GnRH2 gene revealed
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Table 2 | Identification of the GnRH2 gene within 68 additional mammals via
NCBI gene database queries.
Order

Common name

Genus species

NCBI gene
ID

Afrosoricida

Cape golden mole

Chrysochloris asiatica

102818594

Artiodactyla

Alpaca
Arabian camel
Bactrian camel
Bison
Goat
Texas white-tailed
deer
Tibetan antelope
Water buffalo
Wild bactrian camel
Wild yak
Zebu cattle

Vicugna pacos
Camelus dromedarius
Camelus bactrianus
Bison bison bison
Capra hircus
Odocoileus virginianus
texanus
Pantholops hodgsonii
Bubalus bubalis
Camelus ferus
Bos mutus
Bos indicus

102537645
105096036
105083071
104986175
102171992
110145856

Amur tiger
Cheetah
Ferret
Giant panda
Leopard
Pacific walrus

Panthera tigris altaica
Acinonyx jubatus
Mustela putorius furo
Ailuropoda melanoleuca
Panthera pardus
Odobenus rosmarus
divergens
Ursus maritimus
Leptonychotes weddellii

102950818
106980160
101672225
100469838
109274781
101378339

Orcinus orca
Balaenoptera
acutorostrata scammoni
Physeter catodon
Lipotes vexillifer

101276573
103020677

Carnivora

Polar bear
Weddell seal
Cetacea

Killer whale
Minke whale
Sperm whale
Yangtze river dolphin

102986533
103085292

Myotis lucifugus
Myotis davii

102433482
102763285

Dasyuromorphia Tasmanian devil

Sarcophilus harrisii

100916503

Didelphimorphia Gray short-tailed
opossum

Monodelphis domestica

103098126

Phascolarctos cinereus

110221117

Erinaceus europaeus

103128681

Koala

Erinaceomorpha Western European
hedgehog
Eulipotyphla

Star-nosed mole

Condylura cristata

101633945

Macroscelidea

Cape elephant shrew

Elephantulus edwardii

102862182

Perissodactyla

Donkey
Przewalski’s horse
Southern white
rhinoceros

Equus asinus
Equus przewalskii
Ceratotherium simum
simum

106844450
103555821
106802382

Primate

Angolan colobus

Colobus angolensis

105512752

Black snub-nosed
monkey
Bolivian squirrel
monkey
Coquerel’s sifaka
monkey
Crab-eating macaque
Drill
Golden snub-nosed
monkey

Rhinopithecus bieti

108529998

Saimiri boliviensis

101028145

Propithecus coquereli

105827546

Macaca fascicularis
Mandrillus leucophaeus
Rhinopithecus roxellana

102124425
105535577
104674617

Genus species

NCBI gene
ID

Green monkey
Ma’s night monkey
Northern whitecheeked gibbon
Olive baboon
Pig-tailed macaque
Pygmy chimpanzee
Sooty mangabey
monkey
Sumatran orangutan
Sunda flying lemur
Western gorilla
White-headed
capuchin monkey
White-tufted-ear
marmoset

Chlorocebus sabaeus
Aotus nancymaae
Nomascus leucogenys

103247081
105711412
100594202

Papio anubis
Macaca nemestrina
Pan paniscus
Cercocebus atys

100997952
105481609
100971926
105582156

Pongo abelii
Galeopterus variegatus
Gorilla gorilla
Cebus capucinus
imitator
Callithrix jacchus

100441160
103588840
101151325
108286755

Proboscidea

African elephant

Loxodonta africana

100668639

Rodentia

Alpine marmot

107143918

American beaver
Damara mole-rat
Degu
Kangaroo rat
Long-tailed chinchilla
Naked mole-rat
Thirteen-lined ground
squirrel

Marmota marmota
marmota
Castor canadensis
Fukomys damarensis
Octodon degus
Dipodomys ordii
Chinchilla lanigera
Heterocephalus glaber
Spermophilus
tridecemlineatus

Scandentia

Chinese tree shrew

Tupaia chinensis

102500815

Tubulidentata

Aardvark

Orycteropus afer afer

103191804

103792807

109686520
104853177
101565240
105981455
102005135
101717034
101971577

in granulosa-luteal cells of humans (58). Likewise, GnRH2
mRNA and protein levels increased in human neuronal cells
in response to cAMP treatment, a downstream messenger
of the gonadotropins (59). This effect probably occurs at the
transcriptional level given that mutation of a putative cAMPresponsive element in the 5′ flanking sequence of the human
GnRH2 gene suppressed activity of the GnRH2 promoter (59).
However, when normal and cancerous ovarian cells were
treated with LH and FSH, GnRH2 expression was reduced in
the majority of cell lines tested; only CaOV-3 and SKOV-3 cells
were unaffected by treatment, despite expression of receptors
for the gonadotropins (47). GnRH2 may mediate its own
expression in an autocrine/paracrine manner. For example,
granulosa cells secrete GnRH2 (60) and culture of human
granulosa-luteal cells for 10 days increased GnRH2 mRNA
expression (56). A different study demonstrated that treatment of luteinized granulosa cells with GnRH2 downregulated
GnRH2 expression (58).

Prepro-GnRH2

The porcine prepro-GnRH2 is only 56% homologous to
prepro-GnRH1 (NCBI accession numbers XP_005672842 and
NP_999439, respectively) but contains the same components:
a signal sequence, the decapeptide, a conserved cleavage
site, and GAP (20). As with all peptide hormones, the signal

(Continued)
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Common name

103674386
102734468

103285836
102246670
109448424

Diprotodontia

Big brown bat
Brandt’s bat
Chinese rufous
horseshoe bat
Little brown bat
Myotis davii bat

Order

102339298
102408995
102511575
102280393
109567205

Eptesicus fuscus
Myotis brandtii
Rhinolophus sinicus

Chiroptera

TABLE 2 | Continued
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Table 3 | Production of GnRH2 and GnRHR2 in mammalian tissues.a

TABLE 3 | Continued

Tissue or cell
type

Tissue or cell
type

GnRH2

GnRHR2

Reference

Identifiedb Species Identifiedb Species

Central nervous system
Brain (whole)
+
Forebrainc
+
Midbrainc
+
Hindbrainc
+
Spinal cord
+

h
h, r
h, r
r
h

+
+
+
+
+

h
h, r, m
h, r, m
h, r, m
h, m

(11, 20, 29)
(16, 20, 29)
(16, 20, 29)
(16, 20, 29)
(20, 29)

Endocrine
Hypothalamus
Pituitary (whole)
Anterior pituitary
Adrenal gland
Pancreas
Thyroid

+
+
+
+
+
+

p
h
p
h
h
h

+
+
+
+
+
+

m
m, h
p
h, m
h, m
h, m

(29, 35)
(11, 20, 29)
(35)
(11, 20, 29)
(16, 20, 29)
(11, 20, 29)

Thoracic
Heart

+

h

+

h, m

Aorta
Lung
Thymus gland
Trachea

+
+
+
+

h
h
h
h

+
+

h, m
h, m

(11, 16,
20, 29)
(20)
(11, 20, 29)
(11, 20, 29)
(20)

Digestion and metabolism
Salivary gland
+
Stomach
+
Small intestine
+
Duodenum
−
Jejunum
+
Ileum
+
Large intestine
+
Cecum
+
Colon
−
Rectum
−
Liver
+

h
h
h
h
h
h
h
h
h
h
h

+
+

h, m
h

+

h

+

h, m

+

h

+

m, h

Renal
Bladder
Kidney

+
+

h
h

+
+

m
h, m

+

h

(20)

+
+
+
+
+

h
h
h
h
h

(39)
(20)
(20)
(20)
(11, 20, 29)

+
+

h
h

+

h

+
+
+

h
h
h

+

h

Breast/mammary

+

h

+

h, m

Placenta

+

h

+

h

Immune
Peripheral
leukocyte
T lymphocyte
Lymph node
Tonsil
Bone marrow
Spleen
Female reproductive
Ovary
Ovarian surface
epithelial cells
Granulosa cells
Oviduct
Uterus
Endometrium
Myometrium

+

h, m

+

h, m

+
+

m
h, m

Leydig cells
Sertoli cells
Germ cells
Spermatozoa
Epididymis
Seminal vesicles
Bulbourethral
Prostate

Reference

+

h, p

+

h, m, p

+
+
+

p
p
p

+
+
+
+

p
p
p
h, p

+
+
+
+
+
+
+
+

p
p
h, p
h, p
m, p
m, p
p
h, m, p

(11, 20, 29,
35, 45)
(35, 45)
(35, 45)
(35, 45, 46)
(34, 45, 46)
(29, 34)
(29, 34)
(34)
(11, 20,
29, 34)

a
Adapted from Millar (16). Blank cells indicate tissues that have not yet been
examined.
b
Either mRNA or protein was discovered.
c
See Millar (16) for specific regions of the brain that produce GnRH2 and/or GnRHR2.
Abbreviations: +, positive; −, negative; p, pig; h, human; m, marmoset; r, rhesus
macaque.

sequence directs the hormone to the secretory pathway (61).
Interestingly, the signal sequence of prepro-GnRH1 and
prepro-GnRH2 are dissimilar in the pig (Figure 1C). This
distinction could be important because composition of the
signal sequence has been reported to influence the efficiency
of secretion (61). The cleavage site (Gly–Lys–Arg) is conserved
between prepro-GnRH2 and prepro-GnRH1 (Figure 1C),
indicating that carboxypeptidase E, the enzyme responsible
for cleaving GnRH1 from GAP in mice (62), likely processes
prepro-GnRH2 as well.
To date, the GAP of prepro-GnRH2 has not been studied
directly. However, the GAP of prepro-GnRH1 is secreted with the
mature decapeptide (63) and has been associated with prolactin
and gonadotropin secretion (64, 65). Prepro-GnRH1 and preproGnRH2 in the human have similar lengths except the GAP, which
is 50% longer in prepro-GnRH2 (20). Porcine prepro-GnRH2
(110 amino acids) is also longer than prepro-GnRH1 (91 amino
acids), primarily due to a longer GAP (73 versus 55 amino acids,
respectively; Figure 1C). A similar result was also reported for the
tree shrew (66), indicating that a longer GAP in prepro-GnRH2
may be common in mammals (20) and could have functional
relevance.
Notably, White et al. (20) reported the presence of two
GnRH2-GAP variants in humans. Certain tissues (e.g., fetal
brain and thalamus) expressed a longer GAP variant than others
(e.g., kidney) (20). Likewise, Cheon et al. (67) discovered two transcript variants of GnRH2 with differing GAP lengths in the endometrium of women. The porcine GnRH2 gene is also predicted
to produce two forms of prepro-GnRH2. The classical product
is 110 amino acids (NCBI accession number XP_005672842),
whereas the splice variant encodes a 143 amino acid isoform
(NCBI accession number XP_013840618), due to the retention
of intron 2. The only differences between the two products were
detected in the GAP region (Figure 1C). Although, the biological
significance of these variants of GAP for prepro-GnRH2 has not
yet been elucidated.

(20, 29)
(11, 16,
20, 29)

(11, 20, 29)
(40, 41)
(41)
(29)
(11, 20, 29)
(20)
(44)
(11, 20,
29, 38)
(11, 20)
(Continued)
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Identifiedb Species Identifiedb Species

Male reproductive
Testis

(20)
(11, 20, 29)
(11, 20)
(43)
(43)
(43)
(11, 20)
(43)
(43)
(43)
(11, 16,
20, 29)
(11, 16,
20, 29)

Skeletal muscle

GnRH2
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Table 4 | Production of GnRH2 and GnRHR2 in mammalian cell lines.
Cell line

Origin

Species

GnRH2a

GnRHR2a

Reference

TE671

Neuronal medulloblastoma

Human

Lung
A549

Alveolar adenocarcinoma

Human

+

(11)

Digestive
SW480
IPEC-J2

Colorectal adenocarcinoma
Intestinal epithelial cells

Human
Porcine

+
+

(11)
(48)

Immune
HL-60
Jukat

Promyelocytic leukemia
T cell leukemia

Human
Human

+

+
+

(11)
(39, 49)

Mammary
MDAMB-231
MCF-7
MCF-10A

Breast adenocarcinoma
Breast adenocarcinoma
Breast epithelium

Human
Human
Human

+
+
+

Female reproductive
HeLa
Hec-1A
Hec-1B
Ishikawa
HHUA
EFO-21
EFO-27
OVCAR-3
SK-OV-3
CaOV-3
BG-1
IOSE-29
SVOG-4O
SVOG-4m

Cervical adenocarcinoma
Endometrial adenocarcinoma
Endometrial adenocarcinoma
Endometrial adenocarcinoma
Endometrial adenocarcinoma
Ovarian cystadenocarcinoma
Ovarian adenocarcinoma
Ovarian adenocarcinoma
Ovarian adenocarcinoma
Ovarian adenocarcinoma
Ovarian adenocarcinoma
Ovarian surface epithelia
Granulosa-luteal cells
Granulosa-luteal cells

Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human

Male reproductive
ST
ALVA-41
PPC-1
DU-145

Fetal testis
Prostate adenocarcinoma
Prostate adenocarcinoma
Prostate carcinoma

Porcine
Human
Human
Human

+
+
+
+

(53)
(50)
(50)
(49, 50)

Urinary
TSU-Pr1
COS-1b
HEK293

Bladder carcinoma
Kidney
Embryonic kidney

Human
African green monkey
Human

+
+
+

(49, 50)
(11)
(50)

Nervous
+

(41)

(38)
(38)
(38)
+
+

+
+
+
+
+
+
+

+
+
+
−
+
+
+

(11, 50)
(51)
(52)
(51)
(49)
(51)
(52)
(40, 51)
(40, 51)
(40)
(47, 52)
(40)
(41)
(41)

a
The presence of a (+) indicates that either mRNA or protein has been identified, whereas a (−) specifies that the tissue was negative. Blanks designate cell lines that have not yet
been examined.
b
The presence of GnRHR2 protein is putative as GnRH2 treatment of COS-1 cells yielded IP accumulation.

The Structure of GnRH2

and half-life (71, 72) compared with GnRH1, which is rapidly
degraded (73).

GnRH2 (pGlu–His–Trp–Ser–His–Gly–Trp–Tyr–Pro–Gly–NH2)
differs from GnRH1 by three amino acids [His5, Trp7, and
Tyr8; (12)], resulting in 70% sequence identity (20). Amino
acids His5, Trp7, and Tyr8 help stabilize GnRH2, whereas the
N-terminal (pGlu1, His2, Trp3, and Ser4) and C-terminal (Pro9,
Gly–NH210) residues are essential for receptor binding and
activation (68). Structurally, GnRH2 is more negatively charged
and slightly bulkier than GnRH1 (30). GnRH2 has a β-turn
conformation that is similar to GnRH1; however, GnRH2
exists in a preconfigured conformation. Thus, GnRH2 does not
require extensive conformational changes for receptor activation
(68). The conformation of GnRH2 may render it less sensitive
to peptidases (69), likely increasing (6-fold) its stability (70)
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GONADOTROPIN-RELEASING HORMONE
2 RECEPTOR
Identification of GnRHR2 in Mammals

Originally cloned in African catfish (74), a 7-transmembrane
(TM) G protein-coupled receptor (GPCR) specific to GnRH2
(GnRHR2) has also been discovered in mammals (11, 29). The
GnRHR2 gene was first identified in mammals by surveying
the human genome for genes with high homology to GnRHR1
(11, 29). A gene with 40% homology to GnRHR1 was identified
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but it was more similar to GnRHR2 in fish (65% identity) and
amphibians (55% identity), suggesting the identification of a
human GnRHR2 gene (11). Mammals only maintain genes for
GnRHR1 and GnRHR2, although a GnRHR3 gene has been
discovered in other vertebrates (16).

The porcine GnRHR2 gene has three exons and two introns
(Figure 2B). Exon 1 (530 bp) of the porcine GnRHR2 gene
encodes the extracellular N-terminus, TM domains 1–3, part
of TM domain 4, intracellular loop (ICL) 2, and extracellular
loop (ECL) 1. Exon 2 (215 bp) encodes the remainder of TM4 as
well as TM5, ECL2, and part of ICL3. Exon 3 (450 bp) encodes
the remainder of ICL3, TM6–7, ECL3, and the C-terminal tail
(Figure 2B). Intron 1 of the porcine GnRHR2 gene is relatively
large (2.8 kb) compared with intron 2 (470 bp; Figure 2B),
similar to reports from other species (21).
An additional truncated GnRHR2 gene has also been
discovered on chromosome 14 in humans (80), containing
only exons 2 and 3 (46). Interestingly, exons 2 and 3 of this
apparent pseudogene are 100% identical to the corresponding
exons of the complete GnRHR2 gene on chromosome 1 (80).
This distinction may be especially critical when designing
primers/probes for analysis of GnRHR2 gene expression in
human tissues. The truncated GnRHR2 gene (chromosome 14)
is more transcriptionally active and widely expressed than
the full-length gene [chromosome 1; (46)]. This could explain
discrepancies in GnRHR2 mRNA levels of human tissues across
studies performed prior to this finding; Neill et al. (11) utilized
a riboprobe specific to exon 3, whereas Millar et al. (29) used
a DNA probe specific to exon 1 (46). Consistent with the fulllength gene on chromosome 1, this truncated GnRHR2 gene is
flanked by RBM8A, indicating it was duplicated from the chromosome 1 locus via retrotransposition (77). In fact, transcripts

The Gene for GnRHR2

The human, chimpanzee, and rhesus macaque GnRHR2 gene is
located on chromosome 1 (21). In other species, however, the
gene for GnRHR2 is located on chromosome 17 (dog), chromosome 5 (horse), chromosome 3 [cow; (21)], and chromosome
4 [pig; (21, 75)]. The GnRHR2 gene is closely associated in the
antisense orientation with the RBM8A and PEX11B genes in all
species (21, 22, 76). In humans, the promoter regions of GnRHR2
and PEX11B overlap and the 3′ untranslated region (UTR) of
RBM8A overlaps with two exons of the GnRHR2 gene (76, 77).
The RBM8A gene encodes RNA-binding motif protein 8A, which
helps modulate the post-translational regulation of gene expression (78) and the PEX11B gene codes for peroxisomal membrane
protein 11β, which is involved in the regulation of peroxisome
abundance (79). In the pig, the RBM8A gene is located 423 bp
downstream of the GnRHR2 gene (Figure 2A). The 3′ UTRs of
these two genes overlap, in opposite orientation on complementary strands. Upstream of the GnRHR2 gene, the PEX11B gene is
also located on the antisense strand in the opposite orientation
(Figure 2A). The proximal promoters of these two genes overlap,
with start codons 616 bp apart (75).

Figure 2 | Genomic organization of the porcine GnRHR2 gene on chromosome 4. (A) The PEX11B gene (green) is located 616 bp upstream, whereas the RBM8A
gene (red) is positioned 423 bp downstream of the GnRHR2 gene (blue). Arrows indicate start codons for each gene. Reprinted from Brauer et al. (75) with
permission from Elsevier. (B) The GnRHR2 gene contains 3 coding exons and 2 introns, yielding a 377 amino acid product. Exon 1 of the porcine GnRHR2 gene
encodes the extracellular N-terminus (NT), transmembrane (TM) domains 1–3, part of TM4, intracellular loops (ICL) 1–2 and extracellular loop (ECL) 1. Exon 2
encodes the remainder of TM4 as well as TM5, ECL2, and part of ICL3. Exon 3 encodes the remainder of ICL3, TM domains 6–7, ECL3, and the C-terminal tail
(CT). Note that introns and exons are not drawn to scale.
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of this truncated gene contain exon 2 and 3, retain intron 2,
and also include the 3′ UTR of RBM8A, except in the antisense
orientation (46). Likewise, the genome of the African elephant
contains a GnRHR2 pseudogene with several point mutations/
deletions and lacking exon 1 (21).

Table 5 | Identification of the GnRHR2 gene within 61 additional mammals via
NCBI gene database queries.

Presence of the GnRHR2 Gene in
Mammals

Using bioinformatics, the GnRHR2 gene was identified in the
genomes of 22 mammalian species, although sequence analysis
revealed that gene disruptions occurred in 12 of these species
[Table 1; (21)]. Early evidence implied that the GnRHR2 gene
was functional in the human, sheep, and mouse as immunostaining for GnRHR2 was detected in brain tissue of these species
(29). However, the ovine GnRHR2 gene contains a premature
stop codon in exon 1 and a 51 bp deletion in exon 2, preventing translation of a full-length protein (26, 81). In humans (and
chimpanzees), a frameshift mutation occurs due to a missing
nucleotide (compared with the marmoset) in the 5′ flanking
sequence. A premature stop codon is also present due to a single
base change in an arginine codon in exon 2 (26, 81). Furthermore,
the GnRHR2 gene was subsequently determined to be absent
from chromosome 3 in the mouse genome (21, 22) and only a
remnant of exon 1 remains on chromosome 2 in the rat (22, 30).
In other species, the GnRHR2 gene likely encodes a nonfunctional protein as well. The bovine GnRHR2 gene is disrupted
by frameshift mutations in all three exons, in addition to premature stop codons in exons 2 and 3 (26). The squirrel GnRHR2 gene
contains a premature stop codon and an amino acid substitution,
whereas the guinea pig has frameshift mutations in all three exons
and two premature stop codons in exon 3 (21). The rabbit gene
has a 14 bp deletion that results in a frame shift and premature
stop codon, and the cat gene has a premature stop codon (21).
In addition, the GnRHR2 genes in the common shrew, dolphin,
horse, and dog harbor several frameshifts and premature stop
codons (21). In fact, only eight species (orangutan, African green
monkey, rhesus macaque, marmoset, tree shrew, kangaroo rat,
pig, and elephant) possess the appropriate gene sequence to
produce a functional GnRHR2 [Table 1; (21)].
Our laboratory surveyed the updated NCBI gene databases
to re-evaluate which mammals maintain the GnRHR2 gene. The
GnRHR2 gene was confirmed in the genomes of 61 additional
species representing 11 more orders (Table 5). Based on this
report and Stewart et al. (21), the gene for GnRHR2 is present
in the genomes of 83 species to date, encompassing 22 different
mammalian orders. However, it is unclear if the gene is functional
or silenced in these animals. Therefore, future bioinformatics
work is needed to examine the characteristics of the GnRHR2
gene within these species.
Coupled with the aforementioned GnRH2 gene distribution
data, it is clear that few mammalian species have a functional
GnRH2–GnRHR2 system. The maintenance of only part of the
system in some species (e.g., ligand or receptor only) assumes
interaction with the GnRH1–GnRHR1 system to maintain
functionality. Millar et al. (18) proposed that the presence
of GnRH2, but not a functional GnRHR2, in some species
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Order

Common name

Genus species

NCBI gene
ID

Afrosoricida

Cape golden mole
Lesser hedgehog
tenrec

Chrysochloris asiatica
Echinops telfairi

102817241
101659402

Artiodactyla

Alpaca
Arabian camel
Bactrian camel
Bison
Goat
Texas white-tailed
deer
Wild bactrian camel
Wild yak
Zebu cattle

Vicugna pacos
Camelus dromedaries
Camelus bactrianus
Bison bison bison
Capra hircus
Odocoileus virginianus
texanus
Camelus ferus
Bos mutus
Bos indicus

102526131
10510588
105079482
104983739
102184212
110144360

Amur tiger
European domestic
ferret
Giant panda
Pacific walrus
Polar bear
Weddell seal

Panthera tigris altaica
Mustela putorius furo

102969203
101687337

Ailuropoda melanoleuca
Odobenus rosmarus
Ursus maritimus
Leptonychotes weddellii

100484454
101379215
103678407
102742574

Killer whale
Minke whale

Orcinus orca
Balaenoptera
acutorostrata scammoni
Physeter catodon
Lipotes vexillifer

101271242
103006588

Carnivora

Cetacea

Sperm whale
Yangtze river dolphin

102518691
102266467
109555832

102982977
103074337

Cingulata

Nine-banded
armadillo

Dasypus novemcinctus

101438616

Dasyuromorphia

Tasmanian devil

Sarcophilus harrisii

100925975

Didelphimorphia

Gray short-tailed
opossum

Monodelphis domestica

100014969

Diprotodontia

Koala

Phascolarctos cinereus

110219988

Erinaceomorpha

Western European
hedgehog

Erinaceus europaeus

103127802

Eulipotyphla

Star-nosed mole

Condylura cristata

101623053

Macroscelidea

Cape elephant shrew Elephantulus edwardii

102866982

Perissodactyla

Donkey
Przewalski’s horse
Southern white
rhinoceros

Equus asinus
Equus przewalskii
Ceratotherium simum
simum

106847655
103556230
101400748

Pholidota

Malayan pangolin

Manis javanica

108400376

Primates

Angolan colobus
Black snub-nosed
monkey
Bolivian squirrel
monkey
Coquerel’s sifaka
monkey
Crab-eating
macaque
Drill
Golden snub-nosed
monkey
Green monkey
Ma’s night monkey
Mouse lemur

Colobus angolensis
Rhinopithecus bieti

105518331
108531432

Saimiri boliviensis

101045352

Propithecus coquereli

105809593

Macaca fascicularis

102142398

Mandrillus leucophaeus
Rhinopithecus roxellana

105550280
104671044

Chlorocebus sabaeus
Aotus nancymaae
Microcebus murinus

103225877
105730634
109730387
(Continued)
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human cancer cells with reduced GnRHR1 levels, GnRH2 (not
GnRH1) retained the ability to inhibit cell proliferation (52).
Small interfering RNA targeting GnRHR1 inhibited the actions
of GnRH1 on trophoblast invasion, but GnRH2-mediated effects
persisted (84). GnRH1 and GnRH2 also have differing effects
in primary cultures of human decidual stromal cells; GnRH1
increased whereas GnRH2 suppressed mRNA and protein levels
(83). Although the results of the latter study could be related
to divergent signaling of GnRH2 at the GnRHR1, these data
ultimately support the presence of a functional GnRHR2 in
humans.
Many hypotheses have arisen for how the disrupted GnRHR2
gene may retain functionality including: (1) counteractive shifts
in the reading frame, (2) recoding of stop codons, (3) alternative
splicing, (4) alternative protein translation, or (5) production
and functionality of GnRHR2 fragments (82). The mechanisms
that could potentially yield a functional receptor from a seemingly non-translatable mRNA sequence were reviewed by Neill
et al. (82). First, a corrective shift in the reading frame, albeit
rare, has been demonstrated in eukaryotes, allowing for the
production of a full-length protein (85). Indeed, Millar et al. (18)
isolated human GnRHR2 transcripts missing the stop codon.
Second, the use of an alternative start codon (e.g., GUG instead
of AUG) has also been considered. In humans, a GUG codon is
downstream of the frameshift and would yield a 5-TM receptor
with a truncated (22 amino acids) N-terminus. Interestingly, a
similar phenomenon occurs in the translation of African green
monkey GnRHR2 mRNA (11, 21, 82). Furthermore, the GUG
codon within the human transcript meets the two Kozak criteria
necessary for an alternative start codon (86, 87). Third, it has been
proposed that the premature stop codon may be recoded (82),
which occurs in mammals (85, 88, 89). In the human GnRHR2
mRNA transcript, the premature stop codon is UGA but this
codon can also encode for the amino acid, selenocysteine,
potentially preventing the termination of translation (16, 46,
76, 80). However, attempts to identify selenocysteine incorporation thus far have been fruitless (76). Moreover, alternative splicing in exon 1 would yield a 5-TM GnRHR2 transcript without
the reading frame disruption near the N-terminus of the 7-TM
isoform (82). The premature stop codon, however, would still be
present. Therefore, translation of 5-TM receptor mRNA would
also require a stop codon read-through. A fourth hypothesis is
that fragments of both the 5- and 7-TM isoforms are produced
and reassociate non-covalently after translation, a characteristic
that has been shown with other GPCRs, including GnRHR1
(90–92). Data from Grosse et al. (92) showed that two coexpressed GnRHR1 fragments (corresponding to TM domains
1–5 and 6–7) reassociated to produce a full-length, functional
receptor. If protein fragments of the 7-TM GnRHR2 isoform
(containing TM domains 1–4 and 6–7) reassociated, they would
form a 6-TM isoform. However, it is unclear if a 6-TM receptor
would be functional (82).
The final theory is that GnRHR2 fragments are successfully
produced and modulate GnRHR1 activity (82). This hypothesis
is seemingly supported by the work of Pawson et al. (93) who
demonstrated that a GnRHR2 protein fragment (termed the
GnRHR2 reliquium) inhibits post-translational GnRHR1 protein

TABLE 5 | Continued
Order

Common name

Genus species

NCBI gene
ID

Northern whitecheeked gibbon
Olive baboon
Pig-tailed macaque
Pygmy chimpanzee
Small-eared galago
Sooty mangabey
monkey
Sumatran orangutan
Sunda flying lemur
Tarsier
Western gorilla
White-headed
capuchin monkey
White-tufted-ear
marmoset

Nomascus leucogenys

100593225

Papio anubis
Macaca nemestrina
Pan paniscus
Otolemur garnettii
Cercocebus atys

101008793
105479042
100995783
100963950
105592861

Pongo abelii
Galeopterus variegatus
Tarsius syrichta
Gorilla gorilla
Cebus capucinus
imitator
Callithrix jacchus

100460080
103595864
103268450
101137503
108293668

Alpine marmot

107160395

American beaver
Damaraland mole rat
Degu
Naked mole-rat

Marmota marmota
marmot
Castor canadensis
Fukomys damarensis
Octodon degus
Heterocephalus glaber

Scandentia

Chinese tree shrew

Tupaia chinensis

102498810

Sirenia

Florida manatee

Trichechus manatus
latirostris

101357387

Tubulidentata

Aardvark

Orycteropus afer afer

103203244

Rodentia

100399755

109682308
104865794
101580342
101703276

signifies that GnRHR1 has adopted a dual role for the actions
of GnRH1 and GnRH2 through alternative ligand conformations and downstream signaling events. In species that produce
both GnRH2 and its receptor, however, this system was likely
critical to survival to have avoided gene inactivation throughout
evolution.

Does the Human Produce the GnRHR2?

When GnRHR2 was first discovered in mammals, GnRHR2specific immunostaining was detected in the human brain (29),
implying that humans produce a full-length GnRHR2. However,
it was later discovered that coding errors likely interrupt successful translation of human GnRHR2 mRNA (21). Indeed, Neill
et al. (82) reported the inability to identify translatable GnRHR2
transcripts that would yield a full-length receptor in humans, at
least via conventional mechanisms. Recall, the human GnRHR2
gene contains a frameshift mutation in exon 1 and a premature
stop codon in exon 2 (76, 82). Yet, the gene remains transcriptionally active and produces transcript variants due to alternative splicing, suggesting functionality as most pseudogenes are
promoterless (76). These conflicting results have been the subject
of much research and debate.
Despite the apparent gene coding errors, there is evidence for
functionality of the GnRHR2 in humans (82). For example, use
of a GnRHR1 antagonist mitigated the effects of GnRH1, but not
GnRH2, in human decidual stromal (83) and trophoblast (84)
cells. GnRH2, and not GnRH1, effectively suppressed proliferation of SK-OV-3 cells containing only GnRHR2 mRNA (51). In
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abundance via interactions with GnRHR1 inside the nucleus,
endoplasmic reticulum, and/or Golgi apparatus (93). This
fragment spans the cytoplasmic end of the 5-TM domain to
the carboxyl terminus of the full-length receptor and would be
produced by the aforementioned alternative start site (GUG)
downstream of the premature stop codon (93). Interestingly,
others have reported that GnRHR1 fragments with similar
domains (TM6–7) suppress GnRH-mediated signaling when
coexpressed with the full-length GnRHR1 (92). This theory is
supported by early work revealing GnRHR2 immunostaining in
human tissues with an antibody (ZGRH-II-5) directed against
ECL3 (29), which is retained in the GnRHR2 reliquium (93).
Likewise, the ovine GnRHR2 gene may produce a GnRHR2
reliquium as well, given that ZGRH-II-5 antiserum also revealed
GnRHR2 immunostaining in the sheep brain (93). In contrast, a
different antibody directed against ECL2 (absent in the GnRHR2
reliquium) failed to indicate GnRHR2 immunostaining in sheep
(93). Notably, mRNA that encodes for the GnRHR2 reliquium
has been successfully identified in many human organs and cell
lines, suggesting that this protein fragment may be physiologically
relevant (76). In addition, when the full-length cDNA sequence
for human GnRHR2 (including frame shift and premature stop
codon) is transiently transfected into COS cells, expression of
GnRHR1 is enhanced (18). Thus, it is plausible that a functional
(albeit unconventional) GnRHR2 is produced in humans. To
date, however, the controversy remains unresolved and actions

of GnRH2 in humans are predominantly ascribed to GnRHR1
signaling.

Characterization of the Mammalian
GnRHR2 Gene Promoter

While transcriptional regulation of the GnRHR1 gene has been
evaluated in mice (94), rats (95), humans (96), sheep (97),
and pigs (98), much less is known regarding the regulation of
GnRHR2 gene expression. The GnRHR2 gene is transcriptionally
active in several mammals, including humans, sheep, monkeys,
marmosets, musk shrews, and pigs (11, 32, 46, 81, 82, 99).
However, the regulatory elements governing the expression of
this gene have only been studied in the marmoset and pig (75, 99).
Utilizing luciferase reporter constructs containing either the
GnRHR1 or GnRHR2 pig promoter in transient transfection
assays with cell lines from several tissues, the GnRHR2 promoter
was active in all cell types examined, whereas activity of the
GnRHR1 promoter only exceeded the promoterless control in
gonadotrope-derived αT3-1 cells [Figure 3; (75)]. Initial studies
in immortalized swine testis (ST) cells revealed that activity of
the porcine GnRHR2 promoter was partially conferred by nuclear
factor-κB, specificity protein 1 and 3 (SP1/3), and overlapping
early growth response 1/SP1/3 (EGR1/SP1/3)-binding sites (75).
The EGR1 and SP1/3-binding sites are located in a region of the
5′ UTR that is highly conserved compared with the marmoset
GnRHR2 promoter and previously shown to enhance promoter

Figure 3 | Activity of the porcine GnRHR1 and GnRHR2 gene promoters within different mammalian cell lines. Cells were transiently transfected with either the
porcine GnRHR1 (white) or GnRHR2 (black) gene promoter in a luciferase reporter vector and expressed as fold activity over the promoterless control. Abbreviations:
HELA, human cervical cancer; DON, Chinese hamster lung; MSC-1, mouse Sertoli cell; STO, mouse embryonic fibroblast; JAR, human placenta; MA-10, mouse
Leydig cell; MCF7, human breast cancer; IPEC-J2, piglet intestinal epithelium; C2C12, mouse muscle myoblast; 3T3-L1, mouse adipocyte fibroblast; COS-7, green
monkey kidney; PK15, porcine kidney; PGC-2, porcine granulosa cell; ST, swine testis; and αT3-1, murine gonadotrope. An asterisk indicates Least Squares Means
that are significantly greater than the promoterless control (P < 0.05). Reprinted from Brauer et al. (75) with permission from Elsevier.
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activity (99). Given the ubiquitous expression of GnRHR2, it
was not surprising that a transcription factor such as SP1, also
considered to be widely produced, would be involved in regulation. This contrasts greatly from the three steroidogenic factor
1-binding elements required for basal expression of the porcine
GnRHR1 gene in the gonadotrope-derived αT3-1 cell line (98).
So, in accord with divergent expression patterns of the GnRHR1
and GnRHR2 genes, their transcription is differentially regulated
as well.

Table 6 | Structural and functional characteristics of GnRHR1 and GnRHR2 in
mammals.a
Characteristic
Structure
Number of amino acids
5-transmembrane isoform
C-terminal tail
Amino acid conferring receptor
activation in TM2 and TM7
Amino acids conferring ligand
selectivity in ECL3

The GnRHR2 Gene Is Ubiquitously
Expressed in Mammals

Similar to GnRH2, the GnRHR2 gene is widely expressed throughout the body (11, 29). Within the brain, the GnRHR2 was found
in the forebrain, midbrain, and hindbrain (16). Expression was
pronounced in areas that regulate sexual behavior, such as the
putamen, occipital lobe, cerebellum, and caudate nucleus, but
reduced within the anterior pituitary gland (29). In addition,
GnRHR2 mRNA was also found in peripheral tissues including the
heart, stomach, intestine, kidney, spleen, skeletal muscle, thymus,
lung, liver, pancreas, adrenal, thyroid, placenta, uterus, ovary,
breast, seminal vesicles, epididymis, prostate, and testis [Table 3;
(11, 29)]. Relative to GnRHR2 mRNA amounts in the pituitary,
expression levels were lowest in the marmoset bladder and highest
in the testis (29). Likewise, van Biljon et al. (46) detected strong
GnRHR2 signal in the human testis via in situ hybridization and
our laboratory reported abundant GnRHR2 protein levels in
the testis compared with the anterior pituitary gland of the pig
(35). The receptor has been found in reproductive cancer cell lines
derived from the prostate, cervix, endometrium and ovary, as well
as cell lines produced from other organ systems (e.g., respiratory,
digestive, mammary, immune, and urinary; Table 4). GnRHR2
was also identified by our laboratory in cell lines derived from
porcine intestine and testis [Table 4; (48)]. Our group has also
detected GnRHR2 mRNA in various porcine tissues (e.g., testis,
anterior pituitary, spleen, liver, large intestine, small intestine, and
stomach) using conventional PCR (48).

GnRHR1

Reference

377–380
+
+
Asp/Asp

327–328
−
−
Asn/Asp

(16, 74, 104)
(80)
(16, 74, 104)
(74, 105)

Val–Pro–
Pro–Ser

Leu–Ser–Asp/
Glu–Pro

(106)

Relative-binding affinities of native peptidesb
GnRH1
1
GnRH2
24

15
1

(16)
(16)

Relative activities of native peptidesc
GnRH1
1
GnRH2
90–440

12
1

(16, 80)
(11, 16, 80)

Relative activities of GnRHR agonistsc
[d-Ala6] GnRH1
1
[d-Ala6] GnRH2
4
Buserilin
1
Triptorelin
1

309
1
548
395

(80)
(104)
(80)
(80)

>5,050
1
>9,523
Full antagonist

(80)
(104)
(80)
(16)

+
+
+
+
+ (sustained)
+
−
−

+
+
+
+
+ (transient)
−
−
+

(16)
(16, 50)
(16)
(16)
(16)
(16)
(16)

+
Rapid
−
+
+

−
Slow
−
−/+
+

(16)
(16)
(102, 103, 107)
(103, 107)
(103, 107)

Relative activities of GnRHR antagonistsc
Cetrorelix (SB-75)
1
Trptorelix-1
1,660
Antide
1
Antagonist 135-18
Full agonist
Coupling and signaling
Gαq/11
Inositol phosphate (IP)
Ca2+
Protein kinase C
ERK 1/2
p38 MAPK
c-Jun N-terminal kinase
Mammalian homolog r-Src of
Rous sarcoma virus (c-Src)
Receptor internalization
Rapid desensitization
Internalization rate
β-Arrestin-dependentd
Dynamin dependente
Clathrin mediated

The Structure of GnRHR2

The full-length porcine GnRHR2 is 377 amino acids (NCBI accession number AAS68622.1) and has 42% homology to GnRHR1,
which is 328 amino acids in length (Table 6; Figures 4A,B; NCBI
accession number NP_999438.1). Like GnRHR1, the GnRHR2 is
a member of the rhodopsin superfamily of GPCRs containing an
extracellular N-terminus as well as seven TM α-helical domains
connected via three ECLs and three ICLs [Figures 4A,B; (74)].
Differences in amino acid number within the domains of
GnRHR1 and GnRHR2 are depicted in Figure 4D. Strikingly,
GnRHR2 maintains a 52 amino acid C-terminal tail that is
uniquely absent in GnRHR1 but similar to non-mammalian
GnRHRs [Figures 4A,B; (74)]. Cytoplasmic tails are common
among GPCRs and promote rapid receptor internalization and
desensitization (100, 101). For example, the monkey GnRHR2
fully desensitized to GnRH2 treatment after 60 min whereas
the tail-less human GnRHR1 failed to desensitize to a GnRHR1
agonist (Triptorelin) during the entire sampling period [90 min;
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Adapted from Millar (16) and Cheng and Leung (108).
Relative fold increase in affinity compared with the non-cognate ligand.
c
Relative fold increase in activity compared with the non-cognate ligand or analog.
d
Internalization of GnRHR2 can be mediated via β-arrestin but it is not required.
e
GnRHR1 internalization is dependent on dynamin in the rat but not human.
Abbreviations: TM, transmembrane; ECL, extracellular loop; ERK 1/2, extracellular
signal-regulated kinase 1 and 2; MAPK, mitogen-activated protein kinase.
a

b

(80)]. The cytoplasmic tail contributes to internalization differences between GnRHR1 and GnRHR2 as well. GnRHR1 is internalized without interacting with β-arrestin, whereas GnRHR2
can utilize β-arrestin for internalization (102), although it is
not absolutely required (Table 6) (103). The phosphorylation of
serine residues 338 and 339 in the C-terminus by GPCR kinases
is critical for β-arrestin-independent internalization of GnRHR2
(103), whereas other regions within the C-terminal tail or ICL3
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Figure 4 | Structural comparison of GnRHRs in the pig. (A) GnRHR1 (B) GnRHR2 and (C) predicted 5-transmembrane (TM) GnRHR2 in the pig. GnRHR1 and
GnRHR2 are both 7-TM G-protein coupled receptors; however, GnRHR1 lacks a C-terminal tail present in GnRHR2. The 5-TM GnRHR2 isoform lacks TM domains 1
and 2 due to alternative splicing in exon 1 of the GnRHR2 gene, resulting in coupling of a truncated extracellular N-terminus directly to TM3. Glycosylation sites are
represented by branched structures (Y) and the darkened residues in the GnRHR2 isoforms represent predicted sites of phosphorylation for internalization based on
the work of Madziva et al. (102) and Ronacher et al. (103). Structures are predicted according to NCBI database records (GnRHR1, accession number
NP_999438.1; GnRHR2, accession number AAS68622.1; 5-TM GnRHR2, accession number AAS68623.1). Adapted from Neill (80) and Neill et al. (82) with
permission from Oxford University Press and Elsevier. (D) Comparison of residue number within each domain of GnRHR1, GnRHR2, and the predicted 5-TM
GnRHR2 in the pig. Abbreviations: NT, extracellular N-terminus; TM, transmembrane; ICL, intracellular loop; ECL, extracellular loop; CT, C-terminal tail.

are sufficient for β-arrestin-dependent internalization (102).
Therefore, two distinct pathways coordinate internalization of
GnRHR2 (103). In addition, GnRHR2 internalization is dependent upon dynamin and likely mediated by both clathrin-coated
pits and caveolae (103).
Other notable differences between the structure of GnRHR1
and GnRHR2 include alterations in residues that are highly
conserved among GPCRs. GnRHR2 has an Asp/Asp microdomain in TM2 and 7, which is prevalent among GPCRs (74),
whereas the GnRHR1 has a distinct Asn/Asp domain (Table 6).
This region is thought to be important for receptor configuration and activation (105). Likewise, GnRHR2 has a divergent
ligand-binding site (Val–Pro–Pro–Ser) within ECL3 compared
with GnRHR1 (Leu–Ser–Asp/Glu–Pro; Table 6). This sequence
probably determines the selectivity of GnRHR2 for GnRH2,
as all other known ligand-binding sites are conserved between
GnRHR1 and GnRHR2 (106). GnRHR2 and GnRHR1 also differ
in the charge distributions of their extracellular domains, which
may affect ligand binding (30).

comprised primarily of residues from ECL1, couples directly to
TM3 [Figures 4C,D; (82)]. Transcripts for the 5-TM isoform
were originally isolated from porcine pituitaries (109) but we have
also found the 5-TM GnRHR2 transcript in various tissues of the
boar (e.g., testis, spleen, liver, large intestine, small intestine, and
stomach) via conventional RT-PCR (48). The 5-TM transcript
possesses all the characteristics of a translatable protein (109, 110)
and would yield a 286 amino acid receptor (Figures 4C,D).
Functionality of the 5-TM GnRHR2 has not been characterized
thus far, but there is precedence for biologically active 5-TM
GPCRs (111–114). As noted previously, the human may also
produce a 5-TM GnRHR2 transcript; however, it retains an inframe premature stop codon (82).

THE INTERACTION BETWEEN GnRH2
AND GnRHR2
Functionality and Ligand Selectivity
of GnRHR2

A 5-Transmembrane GnRHR2 Isoform

Receptor binding (29) and inositol phosphate (IP) accumulation
(11, 29) assays established the selectivity of GnRH2 for GnRHR2.
The binding affinity of GnRH2 for GnRHR2 is 24-fold greater
than for GnRHR1 [Table 6; (29)]. When COS-1 cells overexpressing porcine GnRHR2 cDNA were treated with GnRH2 or

A 5-TM GnRHR2 isoform has been identified in pigs [Figure 4C;
(109)]. Transcripts from this isoform are produced via alternative
splicing in exon 1 and a different start codon. Therefore, TM1
and 2 are absent and the truncated extracellular N-terminus,
Frontiers in Endocrinology | www.frontiersin.org
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GnRH1, production of IP was stimulated with an EC50 of 0.5 nM
for GnRH2 and 220 nM for GnRH1 (109). Conversely, the EC50
for GnRH2 binding the human GnRHR1 was 7.41 nM compared
with 0.63 nM for GnRH1. The African green monkey (11) and
marmoset GnRHR2 (29) were found to be functional and selective for GnRH2 as well. Thus, GnRH2 is 100- to 400-fold more
active at the GnRHR2 than is GnRH1. In contrast, GnRH1 is only
approximately 10-fold more active at GnRHR1 than is GnRH2
(Table 6).
Since GnRH1 and GnRH2 activate alternative GnRHRs, it
became prudent to assess whether GnRH analogs are actually
specific to their cognate receptors. However, it appears that
GnRH1 and GnRH2 analogs, including GnRHR1 superagonists
(Triptorelin and Buserilin), remain specific (Table 6) (80). At the
GnRHR2, the native peptide (GnRH2) had an EC50 of 0.58 nM
compared with 7.5 and 48 nM for Triptorelin and Buserilin,
respectively. Therefore, GnRH2 is about 13- to 83-fold more
potent at the GnRHR2 than are GnRHR1 superagonists (80).
Non-native GnRH peptides (e.g., GnRH3) were considerably
less potent (0.02%) than GnRH2 at eliciting IP production (80).
Receptor specificity was also verified for GnRHR antagonists.
Trptorelix-1 was identified as a GnRHR2-specific antagonist (104,
115), whereas Cetrorelix (also known as SB-75) and Antide are
reported to be selective for GnRHR1 (80). For example, Antide
mitigates both GnRH1- and GnRH2-induced IP production
in cells overexpressing GnRHR1 but failed to ablate GnRH2induced IP production in COS-7 cells overexpressing GnRHR2
(69). At elevated concentrations, however, Cetrorelix (SB-75)
can non-specifically bind the GnRHR2 (50, 115). In addition,
an established GnRHR1 antagonist (antagonist 135–18) was
found to have agonistic properties at GnRHR2 (29). These data
demonstrate the functionality and selectivity of the mammalian
GnRHR2, but also indicate that both GnRHs can bind both
mammalian receptors. However, GnRHR2 is highly selective for
GnRH2, whereas GnRHR1 binds both ligands relatively well (16).
Therefore, early studies examining the function of GnRH2 may
be limited given that receptor binding was not addressed, and
the actions of GnRH2 may have been inappropriately ascribed
to GnRH1 (82).

pathways than GnRH1 (18). The seminal research uncovering
the divergent signaling of GnRHR2 was conducted in transiently
transfected cell lines (COS-7) by Millar et al. (29). More recent
work utilizing immortalized human cancer cell lines has further
explored GnRH2-induced signaling (50, 117–120). Although it
is often unclear which receptor (GnRHR1 or GnRHR2) mediates
the signal, because the presence of the GnRHR2 in humans is
controversial (82). Another limitation is the use of cancer cells,
which are inherently abnormal. Thus, there is a gap in our knowledge regarding the signaling cascades of GnRHR2 under normal
physiologic conditions.

DIVERGENT PHYSIOLOGICAL EFFECTS
OF GnRH2 ACTIVATING GnRHR1 AND
GnRHR2
Gonadotropin Secretion

It was originally hypothesized that GnRH2 might function similarly to GnRH1 and elicit gonadotropin release from the anterior
pituitary gland (12) or could be the much sought after FSHreleasing factor (16, 121–123). In support of these hypotheses,
GnRH2 is present within regions of the brain (e.g., pre-optic and
medio-basal hypothalamic areas) associated with the regulation
of gonadotropin secretion (16). However, GnRH2 production
in hypothalamic regions is scarce (33) and GnRH2 does not
coexpress with GnRH1 in the hypothalamus (124). In contrast,
GnRH2 is more highly abundant in other regions of the brain,
such as the midbrain (28, 36, 37). Immunopositive GnRHR2
was detected on 69% of mammalian gonadotrope cells (29) but
GnRH2 has never been isolated from hypothalamic portal blood
(69, 125). Our laboratory detected immunoreactive GnRH2 in
the hypothalamus of pigs, but abundance was low compared
with the testis (34, 35). Millar et al. (29) identified GnRHR2
in the pituitary of the marmoset, although it was expressed at
similar levels in numerous tissues unrelated to reproduction.
It is now well established that GnRH2 and GnRHR2 are more
highly expressed in peripheral tissues than the hypothalamus and
anterior pituitary gland, respectively (20, 29, 33, 35), suggesting
little role in gonadotropin secretion.
Upon its discovery, Miyamoto et al. (12) demonstrated that
GnRH2 was less effective than GnRH1 at eliciting release of LH
(68% less) and FSH (59% less) from pituitary cell cultures derived
from rats. Other investigators confirmed these results in the rat
and sheep through in vitro studies (125–127). GnRH2 was 92%
less effective than GnRH1 at stimulating gonadotropin secretion
from primary cultures of ovine pituitary cells (126). In vivo, a
bolus (10 µg) of GnRH2-stimulated LH and FSH release in rams,
although less robustly (40-fold) than GnRH1. There was a modest preference (2-fold) for FSH over LH secretion in response to
treatment with GnRH2 (29). In the rat (121) and rhesus macaque
(128), however, GnRH2 did not preferentially stimulate FSH
release compared with GnRH1.
The effects of GnRH2 on gonadotropin secretion in rats and
sheep are likely mediated through the GnRHR1, because both
species lack GnRHR2 (21) and GnRHR1 can be activated by
GnRH2, although with 10-fold less activity than GnRH1 (29).

Cell Signaling of GnRHR2

Like GnRHR1, GnRHR2 couples to Gαq/11 to initiate the production of IP, calcium mobilization, and the activation of protein
kinase C (PKC; Table 6) (16, 84, 116). After the activation of PKC,
however, GnRH1 and GnRH2 differentially stimulate mitogenactivated protein kinases (MAPKs) (29). GnRH1 transiently
activated extracellular signal-regulated kinases 1/2 (ERK 1/2)
and the proto-oncogene tyrosine-protein kinase, Src (c-Src) in
COS-7 cells overexpressing GnRHR1 [Table 6; (29)]. Conversely,
GnRH2 did not activate c-Src; instead, the interaction between
GnRH2 and GnRHR2 activated ERK 1/2 in a prolonged manner
as well as p38 MAPK in COS-7 cells overexpressing GnRHR2
(Table 6) (16, 29). Neither GnRH1 nor GnRH2 activated c-Jun
N-terminal kinase (JNK) via their cognate receptors [Table 6;
(29)]. Therefore, GnRHR1 and GnRHR2 exhibit differential
signaling upon binding to their respective ligands. Moreover,
activation of GnRHR1 by GnRH2 initiates different signaling
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Indeed, a GnRHR1-specific antagonist completely blocked both
chronic and acute GnRH2-stimulated secretion of gonadotropins
in sheep (69) as well as in pituitary cell cultures that were derived
from rats (127). These data provide strong evidence that GnRH2
is a weak stimulator of gonadotropin secretion in mammals via
interaction with GnRHR1, although it remains plausible that this
interaction, albeit minimal, may still be physiologically relevant
(80). For example, it has been suggested that GnRH2 primes
activity and/or production of GnRHR1. However, cotreatment
of monkey pituitary cells (125, 128) and rams (69) with GnRH2
and GnRH1 did not enhance LH or FSH secretion above GnRH1
treatment alone. Alternatively, Urbanski (129) proposed that
GnRH2 activates GnRHR1 to mediate the preovulatory LH surge.
However, this hypothesis has not yet been evaluated in vivo.
The effect of GnRH2 on secretion of LH and FSH in species
that produce a functional GnRHR2 has also been examined.
Treating musk shrews with GnRH2-stimulated ovulation, with
10-fold less potency than GnRH1, but this effect could be blocked
with a GnRHR1 antagonist (33). Treating rhesus macaques with
GnRH2 elicited increased secretion of gonadotropins in vivo
during the follicular and luteal phase of the menstrual cycle,
but the response was not compared with GnRH1 (37). Others
showed that a high dose (1 µg/kg of body weight) of GnRH1
and GnRH2 were equipotent at stimulating release of LH and
FSH in the female rhesus macaque (128). However, in cultures
of pituitary cells derived from male rhesus macaques, GnRH2
was a less effective stimulator of gonadotropin secretion than
GnRH1 (125). GnRH2 stimulated secretion of LH with an EC50
of 0.37 nM (compared with 0.10 nM for GnRH1) and FSH with
an EC50 of 0.59 nM (versus 0.10 nM for GnRH1) (125). Receptor
antagonism was used to clarify if GnRHR1 or GnRHR2 mediated
these effects. Interestingly, GnRH2-induced gonadotropin secretion was completely blocked by treatment with Antide (125, 128),
a GnRHR1-specific antagonist that has minimal activity (EC50 of
10,000 nM) at the GnRHR2 (80). Thus, the stimulatory effects of
GnRH2 on gonadotropin secretion were attributed to its interaction with GnRHR1.
Similar results were observed in the pig; Cetrorelix (GnRHR1
antagonist) mitigated GnRH2-induced LH and FSH secretion
from porcine gonadotrope cell cultures (109). Data from our
laboratory support these results. Treatment of boars with [d-Ala6]
GnRH2 weakly stimulated secretion of LH compared with
[d-Ala6] GnRH1 (35). In addition, treatment of males with a
GnRHR2-specific antagonist (Trptorelix-1) failed to suppress LH
secretion (35). Likewise, immunization of boars against GnRH2
did not affect gonadotropin secretion compared with control
males (130). Finally, LH secretion was unaffected in transgenic
swine with ubiquitous knockdown of GnRHR2 (53). Collectively,
these data demonstrate that only high doses of GnRH2 can elicit
weak gonadotropin release via the GnRHR1. Therefore, GnRH2
and its receptor do not appear to be physiological stimulators of
gonadotropin secretion in mammals.

be important in sexual behavior (14, 29, 131). The first evidence
demonstrating a role for GnRH2 in female reproductive behavior
occurred when GnRH2, but not GnRH1, infusions into the brain
of female sparrows increased receptivity to songs of male sparrows (132). In mammals, the effects of GnRH2 on sexual behavior
may be dependent on metabolic state. When feed was restricted
by 60%, female musk shrews displayed fewer sexual behaviors (31)
and had reduced GnRH2 mRNA expression (midbrain GnRH2
cells) and protein abundance (ventromedial nucleus, medial
habenula, GnRH2 cells, and midbrain central gray) compared
with ad libitum fed animals (133). Sexual behaviors as well as
GnRH2 mRNA expression (midbrain) and protein levels in some
regions (ventromedial nucleus and medial habenula) returned to
normal after only 90 min of ad libitum feeding after restriction
(133). The lordosis response in mice during nutrient restriction
was enhanced by GnRH2, but not GnRH1 (134); no effect of
GnRH2 on lordosis was observed when female mice were fed
ad libitum. Mice lack GnRH2 and GnRHR2 (30), therefore the
biological significance of these results is unclear. In male musk
shrews, GnRH2 abundance was examined in all regions of the
midbrain prior to and after feed restriction. Unlike females,
GnRH2 abundance and sexual behaviors were not affected by
feed restriction in male musk shrews. This is potentially due to
sexually dimorphic expression patterns of GnRH2 between male
and female musk shrews or the level of feed restriction (133, 135).
The enhancement of sexual behaviors in female musk shrews
treated with GnRH2 during feed restriction were not attenuated
by the addition of a GnRHR1 antagonist (Antide), suggesting the
effect of GnRH2 on sexual behavior is mediated via the GnRHR2
(32). Similarly, reproductive behaviors of female musk shrews
during food restriction were rescued by treatment with antagonist 135–18 (32), which simultaneously acts as an antagonist
of GnRHR1 and an agonist of GnRHR2 (29). This agrees with
results in female marmoset monkeys showing that GnRH2 and
antagonist 135–18, but not GnRH1, increased proceptive (sexual
solicitation) behaviors (136). In contrast, other studies showed
that high doses (25 µg) of GnRH1 do elicit sexual proceptivity of
female marmosets (137), but these effects are likely mediated by
GnRHR2 (136).
The interaction between metabolic state and the effects of
GnRH2 on sexual behavior may be related to the potential effects
of GnRH2 on the mechanism of food intake. Intracerebroven
tricular infusions of GnRH2 reduced feed intake (33%) in female
musk shrews that were underfed (138). A similar reduction
(28%) in food intake of musk shrews was also apparent with
GnRH2 treatment during ad libitum feeding (138). The ability of
GnRH2 to reduce food intake was acute, beginning 90 min after
GnRH2 infusion and persisting for 3 h, regardless of nutritional
plane (138). The effect of GnRH2 on food intake is probably mediated through the GnRHR2 as treatment with Antide (GnRHR1
antagonist) did not prevent a GnRH2-induced reduction in feed
intake (32).
The results of these studies demonstrate that GnRH2 influences female reproductive behavior through the GnRHR2, not
GnRHR1. GnRH2 may be acting as a permissive neuropeptide
that links reproductive behavior with nutritional status in some
species (32, 136). If energy balance is low, GnRH2 production is

Reproductive Behavior and Energy
Balance

Given the neuroanatomical location of GnRH2 (e.g., midbrain
and limbic structures), investigators hypothesized that it may
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decreased, inhibiting reproductive behaviors and increasing feed
intake. If energy is abundant, increased GnRH2 expression will
promote mating behaviors (32).

GnRH1 and GnRH2 directly within its gonads and treating
gonadal cultures with GnRH1 and GnRH2 stimulates secretion of
sex steroids (153). Moreover, seven novel tunicate GnRHs stimulated the release of gametes in C. intestinalis, indicative of direct
action on the gonads (152). Local control of gonadal function
may have been retained in mammals for a specific purpose not
met by the gonadotropins. McGuire and Bentley (149) proposed
that function might be a rapid, transient responsiveness to environmental stimuli.
Of the 31 organs examined in the marmoset monkey, GnRHR2
transcript levels were most abundant in the testis (29). In fact, several laboratories have now reported the presence of GnRH2 and/
or its receptor within mammalian testes (11, 20, 29, 35, 46, 154),
suggesting an autocrine/paracrine role in testicular function.
Abundance of GnRH2 in the testis of the pig was 7-fold greater
than levels within the anterior pituitary gland or hypothalamus
(Figure 5A) (35). This corresponded to 6-fold more GnRHR2
protein in the testis than in the anterior pituitary gland

Testicular Function

For 35 years, evidence has been accumulating that GnRH1
and GnRHR1 have extrapituitary functions. Both GnRH1 and
GnRHR1 are expressed within the testes of some mammals
(e.g., humans, rats, and mice) (139–144) and their interaction
directly elicits testosterone secretion from Leydig cells (145–148).
The contribution of GnRH1 and its receptor to localized control
of gonadal function is not well understood and therefore often
overlooked (149). Localized regulation of the gonads by GnRHs
may have existed early in evolution to control reproduction before
the formation of an organized pituitary gland (7). For instance,
GnRH peptides control reproductive function of invertebrates
(e.g., mollusks, echinoderms, and prochordates) that lack an
anterior pituitary gland (150–152). Ciona intestinalis synthesizes

Figure 5 | Both GnRH2 and GnRHR2 are abundantly produced within the porcine testis. (A) GnRH2 levels were determined via ELISA of homogenates from the
hypothalamus, anterior pituitary gland, and testis of males (n = 6). a,bBars with alternate letters differ (P < 0.0001). (B) Representative western blot of anterior
pituitary gland and testicular tissue from boars (n = 5) using an antibody directed against GnRHR2 (upper panel). Immunoblot quantification revealed a difference in
GnRHR2 protein levels between tissue types (*P < 0.0001; lower panel). (C) GnRH2 is primarily localized to the tubular compartment of the porcine testis.
Representative immunofluorescence image (400×; merge of fluorescence and transmitted light) of porcine testes (n = 5) using an antibody directed against GnRH2
(red). (D) GnRHR2 localizes to both the tubular and interstitial compartments of the porcine testis. Representative immunohistochemistry image (400×) of porcine
testes (n = 7) using an antibody directed against GnRHR2 (purple). Reprinted from Desaulniers et al. (35) with permission from Oxford University Press.
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(Figure 5B). We also observed the most intense GnRH2 immunostaining within the seminiferous tubules of the boar, primarily
localizing to germ and Sertoli cells (Figure 5C) (35), although
some signal was present within the interstitium. Likewise, we have
detected immunoreactive GnRHR2 on germ and Sertoli cells as
well as the plasma membrane of porcine Leydig cells (Figure 5D).
Subcellular localization of GnRHR2 in immortalized ST-derived
cells, recently shown to exhibit Sertoli cell-like properties (155),
revealed plasma membrane as well as perinuclear immunostaining (Figure 6) (48). These data establish that GnRH2 and its
receptor are abundantly produced in the porcine testis, indicating
an important autocrine/paracrine role in testis biology.
The first association of GnRH2 with testicular function was
reported in humans. Although the levels of GnRHR2 mRNA were
not evaluated, testicular GnRH1, GnRH2, and GnRHR1 transcript
abundance was increased in infertile (azoospermic) men, corresponding with elevated intra-testicular testosterone levels and
increased expression of genes encoding steroidogenic enzymes
(CYP11A1 and HSD3B) (154). Notably, GnRH1 and GnRH2
mRNA levels were positively correlated with expression of HSD3B,
intra-testicular testosterone levels, and concentrations of FSH in
serum, indicating that the testicular GnRH system helps regulate
spermatogenesis and steroidogenesis in humans (154). Consistent
with this, GnRHR2 transcripts have been detected in post-meiotic
germ cells and human sperm (46). Our laboratory has immunolocalized GnRHR2 to ejaculated porcine spermatozoa, implying a
role for GnRH2 in sperm function of boars (34, 45). In contrast,
it was concluded that GnRH2 did not impact spermatogenesis in
mice (156); however, mice lack both GnRH2 and its receptor (21),
which limits the interpretation of these results.
Based upon the aforementioned discovery of GnRHR2 on
porcine Leydig cells (35), our laboratory became interested
in whether GnRH2 and its receptor are autocrine/paracrine
regulators of steroidogenesis in the pig. Previous research has

indirectly revealed a role for GnRH2 and its receptor within
the testes of mature swine. For example, testosterone secretion
was reduced in males immunized against GnRH2, but concentrations of LH in serum remained unchanged (130). Primary
cultures of Leydig cells from boars immunized against GnRH2
demonstrated impaired secretion of testosterone basally and
when stimulated with LH (130). In a different study, treatment
of males with a GnRHR1 antagonist (SB-75; Cetrorelix) blunted
hCG-induced secretion of testosterone (157). In a subsequent
trial, release of testosterone in boars was continuously reduced
during chronic administration of SB-75, yet secretion of LH was
only transiently suppressed (158). In addition, SB-75 attenuated
hCG-stimulated secretion of testosterone from porcine testicular
explants (158). These data imply that a testicular GnRHR was
directly regulating steroidogenesis locally within the swine testis.
Given that GnRHR1 is not expressed within the porcine testis
(158), the results of these studies may be ascribed to GnRHR2.
Therefore, we hypothesized that GnRH2, produced locally in the
testis, binds to the GnRHR2 on porcine Leydig cells to stimulate
LH-independent secretion of testosterone.
To test this hypothesis, we treated porcine testicular explants
with hCG in the presence or absence of GnRH2. Secretion of
testosterone was significantly stimulated after treatment with
GnRH2 or hCG but there was no synergistic effect of treating
with hCG and GnRH2 (35). These results established that GnRH2
was a stimulator of acute testosterone secretion ex vivo. We next
tested the effect of GnRH2 in vivo. White crossbred boars were
fit with indwelling jugular cannulae to perform serial bleeding
trials following treatment with GnRH analogs. GnRH2 infusion robustly elicited testosterone secretion, similar to GnRH1
treatment, despite minimal LH secretion when compared
with GnRH1-stimulated males [Figure 7; (35)]. Furthermore,
GnRH2-induced secretion of testosterone was blunted by pre
treatment with the GnRHR1 antagonist, SB-75 (35), which can

Figure 6 | Subcellular localization of the GnRHR2 in a swine testis (ST)-derived cell line. Immunocytochemistry was performed on ST cells (CRL-1746; American
Type Culture Collection, Rockville, MD, USA) with an antibody directed against GnRHR2 (1:100–1:200; sc-162889; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and labeled with an Alexa Fluor 488 secondary antibody (green); nuclei were stained with DAPI (blue). The experiment was replicated three times. Two
representative confocal microscopy images are shown. Note the plasma membrane and perinuclear staining (arrows). The scale bar represents 10 µm. Adapted
from Cederberg et al. (48).
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GnRHR2 knockdown boars had smaller testes (Figure 8A)
despite a normal body weight (Figure 8B), implying impaired
testicular function. Moreover, testosterone concentrations tended
to be lower (Figure 8C) in transgenic versus littermate control
males, yet LH concentrations were unaffected [Figure 8D; (53)].
These results support our hypothesis that activation of GnRHR2
on porcine Leydig cells stimulates LH-independent testosterone
secretion. These swine represent the first genetically engineered
animal model to study the function of GnRH2 and its receptor
in mammals and are currently being utilized to identify the
molecular mechanisms linking GnRHR2 and steroidogenesis in
male pigs. Given that testosterone and its metabolites govern male
fertility (e.g., sex differentiation, reproductive tract maintenance,
libido, spermatogenesis, and accessory sex gland function),
GnRH2 and its receptor are novel molecular targets to enhance
reproductive efficiency in swine.

Female Reproduction

Although GnRH2 and its receptor are expressed within female
reproductive tissues (Table 3), few studies have directly examined
the role of the GnRH2/GnRHR2 system in the female. Several
lines of evidence suggest that GnRH2 and its receptor are novel
regulators of placental function, implantation, and ovarian
steroidogenesis. GnRH2 is produced by the human placenta in
a pulsatile manner and is six times more stable than GnRH1
when exposed to placental enzymes (70). GnRH2 stimulated the
production of hCG in human placental explants (70, 160–162),
whereas GnRH1 treatment did not (70). Moreover, a high affinity receptor specific for GnRH2 (70), as well as immunoreactive
GnRHR2 (163), have been detected in the human placenta.
When compared with GnRH1, GnRH2 potently enhanced
invasion of human trophoblasts (84) through extracellular matrix
remodeling (164). Notably, antagonizing or knocking down
GnRHR1 abrogated GnRH1-mediated effects on trophoblast cells
but did not influence GnRH2-stimulated invasion (84, 165, 166).
In addition, GnRH2 (mRNA and protein) was found in the uterine
endometrium (stromal and glandular epithelial cells) of women
during all phases of the menstrual cycle, although GnRH2 production increased during the secretory phase, indicative of a role
in implantation (67). The GnRHR2 may be produced in human
endometrium as well given that both high and low affinity-binding
sites for GnRH1 were identified in human endometrial cancer
cells (167). Given that GnRH1 binds GnRHR2 with 15-fold less
affinity (29), the low affinity-binding site for GnRH1 detected in
this study may be the GnRHR2. Indeed, others have demonstrated
that immunoreactive GnRHR2 is present in human endometrial
adenocarcinomas (163). Treatment of rhesus macaques with a
GnRHR2 agonist near ovulation conferred contraceptive actions
in 100% of females; this effect was not mediated by the inhibition
of progesterone secretion (168). In a subsequent study, pregnancy
was prevented in all females receiving GnRH2 treatment, whereas
62.5% of saline-treated controls became pregnant. Interestingly,
the low doses of GnRH2 (2–8 μg/day) inhibited secretion of
progesterone, whereas high doses (16–32 μg/day) had no effect
(169). Nevertheless, pregnancy was prevented in all treatment
groups, indicating that the contraceptive activity of GnRH2 is not
confined to the suppression of progesterone production alone.

Figure 7 | GnRH2 stimulates secretion of testosterone similar to GnRH1
despite reduced luteinizing hormone (LH) release in mature male pigs.
Plasma concentrations of LH (A) and testosterone (B) after intravenous
administration of [d-ala6] GnRH1 (solid line; n = 8) or [d-ala6] GnRH2 (dotted
line; n = 6) to cannulated adult males. After pretreatment sampling,
treatments were administered (arrow; 0 min) and blood was serially collected.
Data are presented as the Least Squares Means (±SEM). For LH, Treatment,
P < 0.001; Time, P < 0.0001; Treatment × Time, P < 0.03. For testosterone,
Treatment, P = 0.1929; Time, P < 0.002; Treatment × Time, P = 0.7190.
*Within treatment, concentrations differ from pre-injection levels (P < 0.05).
GnRH1 differences are indicated above error bars and GnRH2 differences
are labeled below error bars. Reprinted from Desaulniers et al. (35) with
permission from Oxford University Press.

antagonize GnRHR2 (50, 115). We hypothesize that SB-75
reduced GnRH2-induced testosterone secretion by antagonizing
GnRHR2 directly in the testis because the secretory pattern of
LH was unaffected compared to trials where only GnRH2 treatments were administered (35). Finally, intratesticular injections
of either GnRH1 or GnRH2 stimulated secretion of testosterone
compared with saline-treated controls; however, GnRH2 did
so without eliciting the release of LH, unlike GnRH1 (159).
Together, these data support our hypothesis that GnRH2 is
stimulating testosterone production directly at the testis in the
absence of the classical androgen regulator, LH.
To further study the role of GnRH2 and its receptor in pigs,
our laboratory generated a GnRHR2 knockdown swine line (53).
These animals ubiquitously express short hairpin RNA targeting
the porcine GnRHR2. Consequently, testicular GnRHR2 mRNA
levels were reduced by 70% in adult males compared with littermate control animals (53). During pubertal development,
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Figure 8 | GnRHR2 knockdown (KD) swine have smaller testes and reduced serum testosterone concentrations but similar body weights and circulating
luteinizing hormone (LH) levels compared with littermate control animals during pubertal development. At 40, 100, 150, 190, 225, and 300 days of age, blood was
collected from GnRHR2 knockdown (n = 10) and littermate control (n = 7) males; at the same time points, body weight and predicted testis volume were measured.
Serum testosterone and LH concentrations were determined by radioimmunoassay. Data are presented as the Least Squares Means (±SEM). The P-value for the
main effect of line is indicated. (A) Predicted testis volume, (B) body weight, (C) serum testosterone concentrations, and (D) serum LH concentrations. Adapted
from Desaulniers et al. (53); no permission is required from the copyright holder.

In other species, GnRH2 appears to modulate secretion
of progesterone as well. Kang et al. (58) reported that GnRH2
inhibited basal and hCG-stimulated progesterone secretion from
human granulosa-luteal cells. In the baboon, GnRH2 is present
in the ovary and released from granulosa cells in vitro. Exogenous
GnRH2 administration suppressed production of progesterone
from cultured granulosa cells by 75% (60), whereas GnRH1 failed
to suppress progesterone release. Binding kinetics indicated two
binding sites for GnRH2, a high and a low affinity site, compared
with only one binding site for GnRH1, suggesting the presence of
a GnRH2-specific receptor in the baboon ovary (60). Collectively,
these data are compelling; however, more studies are needed to
determine how GnRH2 and its receptor impact female reproduction in mammals. Toward this end, research in our laboratory is
currently underway to define the role of GnRH2 and its receptor
in reproductive function of the female pig.

Growing evidence indicates that treatment of cancer cells with
GnRH2 analogs inhibits their proliferation. This has been demonstrated in prostate (54, 172), ovarian, breast, and endometrial
cancer cells (38, 40, 170, 171). Interestingly, GnRH2 appears to
have a more potent anti-proliferative effect than GnRH1 (51). The
cellular mechanisms by which GnRH2 mediates this effect have
been the subject of recent research efforts. Treatment of breast
cancer cells with either GnRH1 or GnRH2 inhibited ribosomal
phosphoproteins, which are needed for proper protein translation
and cell proliferation (38). GnRH2 also increased metalloproteinase production, key regulators of tumor invasion, in ovarian cancer
cells (173). In addition, treatment with a GnRH2 agonist reduced
cell proliferation and inhibited the mitogenic effects of epidermal
growth factor in human endometrial and ovarian cancer cells
(120). In addition, GnRH2 and its receptor may have emerging
roles in the modulation of cell proliferation via extracellular vesicles. For example, glioblastoma-derived microvesicles increased
proliferation of tumor cells in vitro; the same microvesicles were
also found to carry GnRH2, GnRH1, GnRHR2, and GnRHR1
mRNA (174). Thus, GnRH/GnRHR transcripts packaged in
extracellular vesicles could be an unexploited mechanism to affect
tumor progression in humans.
In addition to anti-proliferative actions, GnRH2 analogs
may also exert pro-apoptotic effects on cancer cells. Treatment

Cancer

It is well established that GnRH1 and its receptor are expressed in
cancer cells derived from reproductive tissues and administration of
GnRH1 analogs inhibits their proliferation (51, 170, 171). GnRH2
and its receptor may also influence the progression of reproductive
cancers, given that both are expressed in cancer cells (Table 4) and
tumors derived from reproductive tissues (38, 44, 51, 170, 171).
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with several GnRHR2 antagonists inhibited growth of human
endometrial and ovarian cancer cells in vitro and in vivo via
caspase 3-dependent mechanisms (175); a different GnRHR2
antagonist (SN09-2) induced apoptosis in prostate cancer cells
(172). Likewise, GnRH2 can increase apoptosis via the caspasedependent pathway in human granulosa cells (176). In breast cancer cells, yet another GnRHR2 antagonist induced apoptotic cell
death in vitro and in vivo (177). In addition to anti-proliferative
and pro-apoptotic effects, GnRH2 might also regulate cellular
autophagy. Human prostate cancer cells treated with a GnRHR2
antagonist (Trptorelix-1) displayed increased mitochondrial dysfunction as well as autophagosome formation (178). These cells
had decreased Akt phosphorylation and increased c-Jun phosphorylation, additional hallmarks of cell autophagy. In numerous
cases, the effects of GnRH2 on cancer cells were not mediated
through the GnRHR1, implying a role for human GnRHR2
(50, 52, 120, 177). Thus, GnRH2 and possibly its receptor, regulate
cancer cell proliferation/survival and represent emerging targets
for the development of new cancer therapies.

Within peripheral tissues, GnRH2 and its receptor are important
regulators of reproductive organs in both males and females. For
example, GnRH2 and its receptor directly regulate steroidogenesis
within the porcine testis. In the female, GnRH2 and its receptor
may mediate placental function, implantation, and ovarian steroidogenesis. Furthermore, both GnRH2 and GnRHR2 are expressed
in human reproductive tumors and are emerging targets for cancer
treatment. Therefore, GnRH2 and its receptor are critical modulators of reproductive function in mammals, albeit via a divergent
mechanism from the classical GnRH1 and GnRHR1 interaction.
More work is needed to better understand the importance of localized regulation by the GnRH2/GnRHR2 system, but its contribution to mammalian reproduction is unequivocal.
Despite these data, the ubiquitous nature of GnRH2 and
GnRHR2 suggests that many more biological functions remain
undefined. The deletion of the GnRH2 and GnRHR2 genes from
the rat and mouse has undoubtedly inhibited the study of this
system in a widely available and economical laboratory animal.
However, the recent development of a GnRHR2 knockdown
swine line provides an essential animal model to explore the
functions of GnRH2 and its receptor in mammals. Given the
recent discovery of the GnRH2 and GnRHR2 genes in numerous
mammalian species, this system may be physiologically relevant
and unexploited in a wide range of species.

CONCLUSION
GnRHs are ancient peptides which may have first functioned
to directly regulate the gonads before evolving into specialized
modulators of gonadotropin secretion. GnRH2 is the most
ancient of the GnRHs and has been completely conserved from
boney fish to man, signifying a critical biological role. Moreover,
GnRH2 is structurally unique from GnRH1, which promotes
its stability and half-life. A highly selective receptor specific for
GnRH2 is also produced in mammals. The GnRHR2 is dissimilar
from GnRHR1, containing an intracytoplasmic tail and eliciting
divergent cell signaling cascades. The genes for GnRH2 and/or
GnRHR2 have been deleted or inactivated in many species, but
both are functional in old world monkeys, musk shrews and pigs,
implying an essential role in these animals. Moreover, evidence
continues to suggest the presence of GnRHR2 in humans despite
apparent coding errors in the gene. Data from numerous species
(including humans) demonstrates that GnRH2 and its receptor
are ubiquitously expressed. Notably, both are produced in low
abundance in regions of the brain associated with gonadotropin
secretion and highly expressed in peripheral reproductive organs.
Thus, GnRH2 and its receptor are both structurally and functionally distinct from their classical counterparts.
Contrary to their name, GnRH2 and GnRHR2 are not
physiological stimulators of gonadotropin secretion in mammals.
Instead, GnRH2 and its receptor have been implicated in various
functions, mostly pertaining to mammalian reproduction. The
first defined function of GnRH2 and its receptor was the modulation of sexual behavior, based on nutritional status, in females.
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